Praxis Precision Medicines, Inc. PRAX
At closeNov 3, 2026, 4:29 PM EST
After hours · Nov 3, 4:29 PM ET
- YTD
- -4.83%
- 1 year
- +54.13%
- Market cap
- 7.83B
- EPS (ttm)
- -12.95
- Shares out
- 27.92M
- Forward P/E
- -29.52
- YTD return
- -4.83%
- 1-year return
- +54.13%
- Volume
- 220.55K
- Avg volume
- 460.19K
- Open
- 277.76
- Previous close
- 273.99
- Day's range
- 276.00 – 286.04
- 52-week range
- 154.45 – 392.70
- Beta
- 2.84
- Analysts
- Strong Buy
- Price target
- 650.00 (+131.7%)
- Earnings date
- Nov 9, 2026
2Y +208.90 (+298.34%)
Key statistics
- Enterprise value
- 6.89B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -199.44M
- Total cash
- 758.55M
- Total debt
- 1.09M
- Return on equity
- -38.86%
- Short % of float
- 14.08%
- 50-day average
- 299.25
- 200-day average
- 314.72
Analyst view
Consensus: strong buy
- Target (low)
- 188.00
- Target (mean)
- 650.00
- Target (high)
- 1,201.00
- Strong buy4
- Buy15
- Hold1
- Sell1
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -3.63.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -3.54 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -3.67 | -2.87 | +0.80 | +21.80% |
| May 7, 2026 | Mar 31, 2026 | -3.58 | -3.20 | +0.38 | +10.61% |
| Feb 19, 2026 | Dec 31, 2025 | -3.13 | -3.50 | -0.37 | -11.97% |
| Nov 5, 2025 | Sep 30, 2025 | -3.45 | -3.36 | +0.09 | +2.61% |
| Aug 4, 2025 | Jun 30, 2025 | -3.40 | -3.31 | +0.09 | +2.65% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | JP Morgan | init | — | Overweight |
| Oct 15, 2026 | UBS | init | — | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 6, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 6, 2026 | BTIG | main | Buy | Buy |
| Sep 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- praxismedicines.com
News
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation 
JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700 
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target 
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target 
BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $826 
Praxis Precision Medicine Q2 2026 Earnings Call Transcript 
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM) 
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target - Needham Reiterates Buy on Praxis Precision Medicine, Maintains $582 Price Target
Your note
Sign in to keep a note on PRAX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAGE CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 15, 2025 | 0 |
| ARBUCKLE STUART A | Director | Stock Award(Grant) | Jun 9, 2026 | 2,537 |
| KELLY TIMOTHY EDWIN | Chief Financial Officer | Stock Award(Grant) | May 13, 2026 | 31,167 |
| KINDLER JEFFREY B | Director | Stock Award(Grant) | Jun 9, 2026 | 2,537 |
| MASTROCOLA LAUREN | Officer | Stock Award(Grant) | May 13, 2026 | 13,572 |
| MITCHELL DEAN J | Director | Stock Award(Grant) | Jun 9, 2026 | 18,622 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jupiter Topco LLC | 12.25% | 3,421,374 | 959.73M | Jun 29, 2026 |
| FMR, LLC | 8.30% | 2,316,907 | 649.92M | Jun 29, 2026 |
| Blackrock Inc. | 8.21% | 2,292,585 | 643.09M | Jun 29, 2026 |
| Perceptive Advisors Llc | 7.29% | 2,035,986 | 571.11M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 6.28% | 1,753,198 | 491.79M | Jun 29, 2026 |
| Orbis Allan Gray Ltd | 5.48% | 1,529,788 | 429.12M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 885,411 | 248.37M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.33% | 650,750 | 182.54M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 639,578 | 179.41M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.53% | 427,949 | 120.04M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.47% | 411,429 | 115.41M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.45% | 405,016 | 113.61M | Jun 29, 2026 |